AR056091A1 - Agente farmaceutico que contiene hialuronano como ingrediente activo - Google Patents
Agente farmaceutico que contiene hialuronano como ingrediente activoInfo
- Publication number
- AR056091A1 AR056091A1 ARP060104194A ARP060104194A AR056091A1 AR 056091 A1 AR056091 A1 AR 056091A1 AR P060104194 A ARP060104194 A AR P060104194A AR P060104194 A ARP060104194 A AR P060104194A AR 056091 A1 AR056091 A1 AR 056091A1
- Authority
- AR
- Argentina
- Prior art keywords
- active ingredient
- hyaluronan
- hialuronane
- agent containing
- pharmaceutical agent
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 6
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 6
- 229940099552 hyaluronan Drugs 0.000 abstract 6
- 229920002674 hyaluronan Polymers 0.000 abstract 6
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001012 protector Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000000946 synaptic effect Effects 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
- 150000004044 tetrasaccharides Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Una composicion farmacéutica que contiene hialuronano como un ingrediente activo. Un hialuronano preferido es un tetrasacárido (HA4) que contiene 2 unidades, siendo una unidad simple -ácido D-glucuronico-beta-1,3-D-N-acetilglucosamina-beta-1,4- . Reivindicacion 15: Un inhibidor de la expresion de un gen asociado a citoquinas que comprende hialuronano como un ingrediente activo. Reivindicacion 22: Un realzador de la viabilidad celular que comprende hialuronano como un ingrediente activo. Reivindicacion 25: Un promotor de la transmision sináptica, que comprende hialuronano como un ingrediente activo. Reivindicacion 28: Un protector sináptica que comprende hialuronano como un ingrediente activo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005277918A JP2007084509A (ja) | 2005-09-26 | 2005-09-26 | 細胞賦活剤 |
| JP2005297991A JP2007106688A (ja) | 2005-10-12 | 2005-10-12 | サイトカイン関連遺伝子及びケモカイン関連遺伝子の発現抑制剤 |
| JP2005348017A JP2007153761A (ja) | 2005-12-01 | 2005-12-01 | シナプス伝達促進剤及びシナプス保護剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056091A1 true AR056091A1 (es) | 2007-09-19 |
Family
ID=37667620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104194A AR056091A1 (es) | 2005-09-26 | 2006-09-26 | Agente farmaceutico que contiene hialuronano como ingrediente activo |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1767211B1 (es) |
| AR (1) | AR056091A1 (es) |
| AT (1) | ATE552005T1 (es) |
| BR (1) | BRMU8603015U (es) |
| CA (1) | CA2560844C (es) |
| NO (1) | NO20064337L (es) |
| RU (1) | RU2342148C2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2641571C (en) | 2006-12-05 | 2010-01-19 | Glycoscience Laboratories, Inc. | Treatment of osteoarthritis |
| JP5117110B2 (ja) * | 2007-05-28 | 2013-01-09 | 生化学工業株式会社 | Ｉ型アレルギー疾患治療剤 |
| SG11201404959TA (en) * | 2012-02-22 | 2014-11-27 | Hyaluronan Res Inst Inc | Sirtuin inducer, tissue repairing agent, hepatocyte growth factor inducer, tissue homeostasis maintenance agent, and tlr4 agonist, having hyaluronic acid fragment as active agent |
| IT201600079773A1 (it) * | 2016-07-29 | 2018-01-29 | Matteo Bevilacqua | Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. |
| PL4085905T3 (pl) * | 2021-05-07 | 2024-06-24 | Trb Chemedica Ag | Kwas hialuronowy do zastosowania w zapobieganiu lub leczeniu dysfunkcji neurologicznych nerwu lub komórki nerwowej |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2229282C (en) * | 1995-09-28 | 2002-01-29 | Sangstat Medical Corporation | Use of hyaluronic acid as an immunosuppressant |
| JP4195107B2 (ja) * | 1996-02-16 | 2008-12-10 | 生化学工業株式会社 | ストレス蛋白質発現増強剤 |
| IT1309588B1 (it) * | 1999-03-05 | 2002-01-24 | Altergon Sa | Cerotto con spessore sottile contenente betametasone ed acidoialuronico per il trattamento di psoriasi, dermatite, dermatosi. |
| JP2003089647A (ja) * | 1999-03-10 | 2003-03-28 | Takada Seiyaku Kk | 関節性疾患治療剤 |
| JP4861596B2 (ja) * | 2000-07-07 | 2012-01-25 | 生化学工業株式会社 | ヒアルロン酸オリゴ糖画分およびそれを含む医薬 |
| US6537968B1 (en) * | 2000-07-24 | 2003-03-25 | Alphamed Pharmaceuticals Corp | Treatment of lupus erythematosus |
| EP1369119B1 (en) * | 2001-03-15 | 2008-12-17 | Seikagaku Corporation | Il-12 expression controlling agents |
| US7060691B2 (en) * | 2002-10-10 | 2006-06-13 | Giuseppe Petrigni | Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases |
| US7511026B2 (en) * | 2003-03-25 | 2009-03-31 | Seikagaku Corporation | Therapeutic agent for nerve damage |
| HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
| DE102004002001A1 (de) * | 2004-01-14 | 2005-08-11 | Reinmüller, Johannes, Dr.med. | Mittel zur Behandlung von entzündlichen Erkrankungen |
-
2006
- 2006-09-25 NO NO20064337A patent/NO20064337L/no not_active Application Discontinuation
- 2006-09-25 CA CA2560844A patent/CA2560844C/en not_active Expired - Fee Related
- 2006-09-25 RU RU2006134169/15A patent/RU2342148C2/ru not_active IP Right Cessation
- 2006-09-26 EP EP06020126A patent/EP1767211B1/en not_active Not-in-force
- 2006-09-26 BR BRMU8603015-9U patent/BRMU8603015U/pt not_active Application Discontinuation
- 2006-09-26 AT AT06020126T patent/ATE552005T1/de active
- 2006-09-26 AR ARP060104194A patent/AR056091A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20064337L (no) | 2007-03-27 |
| CA2560844A1 (en) | 2007-03-26 |
| ATE552005T1 (de) | 2012-04-15 |
| RU2342148C2 (ru) | 2008-12-27 |
| RU2006134169A (ru) | 2008-03-27 |
| EP1767211A1 (en) | 2007-03-28 |
| BRMU8603015U (pt) | 2007-12-11 |
| EP1767211B1 (en) | 2012-04-04 |
| CA2560844C (en) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29851B1 (fr) | Composes et compositions contenant de la diarylamine et utilisation en tant que modulateurs de recepteurs de c-kit | |
| AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
| EP4403197A3 (en) | Injectable formulations for organ augmentation | |
| MX2023000731A (es) | Composiciones utiles para enzimas de internalizacion. | |
| AR082319A1 (es) | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos | |
| AR035039A1 (es) | COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA | |
| MXPA06000013A (es) | Agente terapeutico para sarcoma de tejido suave. | |
| CR10748A (es) | Compuesto de indol | |
| BRPI0609424B8 (pt) | composto inibidor da dipeptidil peptidase-iv e composição farmacêutica compreendendo dito composto como um agente ativo | |
| MX2010007846A (es) | Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas. | |
| TW200735865A (en) | Compositions of an anticonvulsant and methods of using the same for reversing weight gain | |
| NO20081593L (no) | Depotsammensetning | |
| MX2009004439A (es) | Composicion de ibuprofeno. | |
| UA110207C2 (xx) | ФАРМАЦЕВТИЧНА ТАБЛЕТКА, ЯКА МІСТИТЬ 1-(β-D-ГЛЮКОПІРАНОЗИЛ)-4-МЕТИЛ-3-$5-(4-ФТОРФЕНІЛ)-2-ТІЄНІЛМЕТИЛ]БЕНЗОЛ ЯК ІНГІБІТОР НАТРІЙЗАЛЕЖНОГО ПЕРЕНОСНИКА ГЛЮКОЗИ (НЗПГ) | |
| AU2018280875A1 (en) | Solid compositions for oral administration | |
| EP4545589A3 (en) | Compositions comprising glucose and hemicellulose and their use | |
| EA201170821A1 (ru) | Энзастаурин для лечения рака | |
| AR056091A1 (es) | Agente farmaceutico que contiene hialuronano como ingrediente activo | |
| CR10029A (es) | Combinacion de productos activos fungicidas | |
| CR10050A (es) | Combinacion fungicida de productos activos | |
| MX2010008490A (es) | Triazolopiridazinas como inhibidores de par1, su produccion y su uso como medicamentos. | |
| TW200504199A (en) | Method of preventing lipids constituting lipid membrane from degradation and use thereof | |
| NO20082848L (no) | Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre | |
| SV2006001916A (es) | Formulaciones farmaceuticas transdermales | |
| MX2025001193A (es) | Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |